000 04222nam a22006015i 4500
001 978-981-97-5077-1
003 DE-He213
005 20251030112930.0
007 cr nn 008mamaa
008 240901s2024 si | s |||| 0|eng d
020 _a9789819750771
_9978-981-97-5077-1
024 7 _a10.1007/978-981-97-5077-1
_2doi
050 4 _aRS400-431
072 7 _aPSB
_2bicssc
072 7 _aSCI013040
_2bisacsh
072 7 _aPNB
_2thema
245 1 0 _aPROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics
_h[electronic resource] /
_cedited by Mukesh Nandave, Priti Jain.
250 _a1st ed. 2024.
264 1 _aSingapore :
_bSpringer Nature Singapore :
_bImprint: Springer,
_c2024.
300 _aXXII, 385 p. 68 illus., 55 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _a1. Understanding the Ubiquitin Proteasome System - History and Revolution -- 2. PROTACs: Principles and Mechanisms -- 3. Structural Considerations and Chemistry of PROTAC -- 4. Advantages and Disadvantages of PROTACs -- 5. Novel Technologies in PROTAC Design -- 6. Future of trends in the design and development of PROTAC -- 7. Global Regulatory Requirements Applicable for PROTACs -- 8. Tissue-Specific Targeting Strategies with PROTAC Technology -- 9. Clinical Development OF PROTACs -- 10. Toxicological Aspects of PROTACs -- 11. PROTACs in the management of Prostate Cancer -- 12. Exploring the Role of PROTACs for the Treatment of Breast Cancer -- 13. Role of PROTACs in Hematological Malignancies -- 14. Artificial Intelligence and Machine Learning for Exploring PROTAC in Underutilized Cells -- 15. PROTACs in Treatment of Glioma -- 16. Proteolysis Targeting Chimera (PROTACs) an Attractive Technology in CVD Therapeutics: Opportunities and Challenges -- 17. Delivery systems - miniaturised PROTAC, Nano PROTAC, Aptamer-based RNA PROTAC.
520 _aThis book is a comprehensive coverage of the ubiquitin-proteasome system and its involvement in cancer progression, and the application of PROTACs in different types of cancer treatment. The book discusses a unique perspective and comprehensive knowledge of the potential of PROTACs to transform cancer therapies. It provides an overview of the history, mechanisms, chemistry, design considerations, and different technologies involved in PROTACs. Additionally, it explains the ubiquitin-proteasome system, its impact on various diseases, and the principles and mechanisms of UPS. The book also describes the chemistry and design aspects of PROTACs and their role in various types of cancers. Finally, it covers the pharmaceutics aspect of formulation design, global requirements, and toxicological aspects of PROTACs. This book is targeted at cancer researchers, medical oncologists, bioinformatics, computational biologists, pharmacologists, medicinal chemists, formulation scientists, regulatory authorities, and policy makers.
650 0 _aPharmaceutical chemistry.
_967843
650 0 _aPharmacology.
_967844
650 0 _aPharmacovigilance.
_974275
650 0 _aOncology.
_970760
650 0 _aDrug delivery systems.
650 0 _aPharmacy.
_964666
650 1 4 _aPharmaceutics.
_967846
650 2 4 _aPharmacology.
_967844
650 2 4 _aDrug Safety and Pharmacovigilance.
_974276
650 2 4 _aOncology.
_970760
650 2 4 _aDrug Delivery.
_969429
650 2 4 _aPharmacy.
_964666
700 1 _aNandave, Mukesh.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_974724
700 1 _aJain, Priti.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_983504
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9789819750764
776 0 8 _iPrinted edition:
_z9789819750788
776 0 8 _iPrinted edition:
_z9789819750795
856 4 0 _uhttps://doi.org/10.1007/978-981-97-5077-1
912 _aZDB-2-SME
912 _aZDB-2-SXM
999 _c63005
_d63005